Popular Articles From: Five Oaks Investment Corp. Announces Fourth Quarter 2014 Monthly Common Stock Dividend Rate of $0.125 Per Share for October, November and December, and Preferred Stock Dividend to Fairchild Presenting at Citi 2014 Global Conference, Hosting Investor Day and Ringing The NASDAQ Closing Bell


The challenges that face Booz Allen Hamilton’s (NYSE: BAH) clients are as diverse as their organizations.
Sign-up for Fiscal Year 2014: The Power of Booz Allen Hamilton’s Innovation Stands Out in “Reaching Forward: Inventing the Future” investment picks
The majority of consumers want person-to-person (P2P) payments from their primary financial institution , and FIS ™ (NYSE: FIS), the world’s largest provider of banking and payments technology solutions and a global leader in consulting and outsourcing solutions, is leading the way in making it a reality.
Sign-up for FIS Brings Instant P2P Payments Capabilities to EverBank investment picks
Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from the AMBITION study (a randomized, double-blind, multicenter study of first-line combination therapy with AMB r I sentan and T adalafil in patients with pulmonary arterial hypertens ION ), which was conducted in collaboration with GlaxoSmithKline (GSK). In AMBITION, first-line treatment of pulmonary arterial hypertension (PAH) with the combination of ambrisentan 10 mg and tadalafil 40 mg reduced the risk of clinical failure by 50 percent compared to the pooled ambrisentan and tadalafil monotherapy arm (hazard ratio = 0.502; 95 percent CI: 0.348, 0.724; p=0.0002). The combination was also statistically significant versus the individual ambrisentan and tadalafil monotherapy groups for the primary endpoint (p<0.01). Rates of serious adverse events and events leading to discontinuation were similar across treatment arms.
Sign-up for First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy in Pulmonary Arterial Hypertension Outcomes Study investment picks
First Trust/Aberdeen Global Opportunity Income Fund (the “Fund”) (NYSE: FAM) has declared the Fund’s regularly scheduled monthly common share distribution in the amount of $0.11 per share payable on August 15, 2014, to shareholders of record as of August 5, 2014.
Sign-up for First Trust/Aberdeen Global Opportunity Income Fund Declares its Monthly Common Share Distribution of $0.11 Per Share for August investment picks
NEW ORLEANS, July 28, 2014 (GLOBE NEWSWIRE) -- First NBC Bank Holding Company (Nasdaq:NBCB) , the holding company for First NBC Bank ("Company"), today announced financial results for the second quarter of 2014.
Sign-up for First NBC Bank Holding Company Announces 2014 Second Quarter Results investment picks
MEMPHIS, Tenn., July 22, 2014 (GLOBE NEWSWIRE) -- First Horizon National Corp.'s (NYSE:FHN) board of directors has approved payment of a quarterly cash dividend on its common stock of $.05 per share.
Sign-up for First Horizon Declares Quarterly Dividends investment picks
SOUTHERN PINES, N.C. , Aug.
Sign-up for First Bancorp Announces Consolidation of Ten Branches investment picks
NEW YORK , July 22, 2014 /PRNewswire/ -- Finjan Holdings, Inc. (NASDAQ: FNJN) , a technology company committed to enabling innovation through the licensing of its intellectual property, today announced an update on its lawsuit against Blue Coat Systems Inc. (Blue Coat). Finjan Holdings' subsidiary Finjan, Inc. filed a patent infringement lawsuit against Blue Coat on August 28, 2013 (5:13-cv-03999-BLF (NDCA)). In accordance with the local patent rules of the U.S. District Court for the Northern District of California , a Claim Construction or "Markman" Hearing is set for August 22 , 2014.
Sign-up for Finjan Holdings Provides Litigation Update - Blue Coat Markman Hearing Set For August 22, 2014 investment picks
Fifth Third Bancorp (Nasdaq: FITB) is scheduled to report third quarter 2014 financial results on October 16, 2014.
Sign-up for Fifth Third Bancorp to Announce Third Quarter 2014 Results, Host Conference Call on October 16, 2014 at 9:00 AM investment picks
Fifth Third Bancorp (Nasdaq: FITB) today disclosed results of its 2014 company-run mid-cycle stress test as required by the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010.
Sign-up for Fifth Third Bancorp Releases Results of Dodd-Frank Act Mid-Cycle Company-Run Stress Test investment picks
WHITE PLAINS, NY, July 7, 2014 (GLOBE NEWSWIRE) -- Fifth Street Finance Corp.
Sign-up for Fifth Street Finance Corp. Announces a 10% Increase to Its Monthly Dividend, Representing an Annualized Run Rate of $1.10 Per Share investment picks
- Reported net income of $56.5 million for the third fiscal quarter - Fixed indexed annuity sales of $379 million, the highest in eight quarters - Executing on growth and ROE expansion strategy DES MOINES, Iowa, Aug.
Sign-up for Fidelity & Guaranty Life Reports Third Quarter Fiscal 2014 Results investment picks
New Option For Accumulation And Income DES MOINES, Iowa , Sept.
Sign-up for Fidelity & Guaranty Life Launches Income And WealthBuilder investment picks
SAN JOSE, Calif.
Sign-up for FICO Declares Quarterly Cash Dividend investment picks
Rancho Mirage, CA, Aug.
Sign-up for Fertility Financing Now Offered Through New Life Partnership With LightStream investment picks
-- Net equity sales top $1.5 billion for Q2 2014 --
Sign-up for Federated Investors, Inc. Reports Second Quarter 2014 Earnings; Equity Managed Assets Reach a Record $50 Billion investment picks
VANCOUVER, British Columbia, Aug.
Sign-up for FDA Modifies Tekmira's TKM-Ebola Clinical Hold to Partial Hold investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1142090&ProfileId=051205&sourceType=1 AMES, IA --
Sign-up for FDA Gives NewLink Genetics Approval to Proceed to Phase 1 Clinical Studies of Their Ebola Vaccine investment picks
- Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with type 2 diabetes as an adjunct to diet and exercise - The single-dose pen does not require mixing nor measuring and comes with a no-see, no-handle needle INDIANAPOLIS , Sept.
Sign-up for FDA Approves Trulicity™ (dulaglutide), Lilly's Once-Weekly Therapy for Adults with Type 2 Diabetes investment picks
AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) approved MOVANTIK ™ (naloxegol) Tablets C-II as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.
Sign-up for FDA Approves MOVANTIK™ (naloxegol) Tablets C-II for the Treatment of Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain investment picks
Incyte Corporation (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for ruxolitinib as a potential treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea.
Sign-up for FDA Accepts Supplemental New Drug Application for Jakafi® (ruxolitinib) and Priority Review Granted investment picks
ARLINGTON, Va., July 21, 2014 (GLOBE NEWSWIRE) -- FBR & Co.
Sign-up for FBR & Co. Announces Self Tender Offer to Purchase up to One Million Shares investment picks
ARLINGTON, Va., Aug.
Sign-up for FBR & Co. Announces Final Results of Self-Tender Offer investment picks
Fantex Brokerage Services (FBS) announced this morning that shares of Fantex EJ Manuel Convertible Tracking Stock 1 (ticker: EJMLL) began trading at approximately 9:00 am PT at Fantex.com. “After completing the Fantex Vernon Davis IPO (ticker: VNDSL) earlier this year, all of us at FBS are thrilled that our second security tied to the cash flows of a professional athlete brand is now open for trading at Fantex.com,” said John Rodin, President, Fantex Brokerage Services.
Sign-up for Fantex EJ Manuel Convertible Tracking Stock Begins Trading at Fantex.com investment picks
Fairchild (NASDAQ: FCS), a leading supplier of high performance power and mobile products, announced today that the Company’s executive team will be in New York City the week of Sept.
Sign-up for Fairchild Presenting at Citi 2014 Global Conference, Hosting Investor Day and Ringing The NASDAQ Closing Bell investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Popular Articles From: Five Oaks Investment Corp. Announces Fourth Quarter 2014 Monthly Common Stock Dividend Rate of $0.125 Per Share for October, November and December, and Preferred Stock Dividend to Fairchild Presenting at Citi 2014 Global Conference, Hosting Investor Day and Ringing The NASDAQ Closing Bell
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices